A Study of Therapeutic Amplitude-modulated Electromagnetic Fields in Advanced Tumors (THBC001)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00440570 |
Recruitment Status :
Completed
First Posted : February 27, 2007
Last Update Posted : June 29, 2011
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Cancer Brain Tumor | Device: Low levels of amplitude-modulated electromagnetic fields Device: Emitter of low levels of amplitude-modulated electromagnetic fields | Early Phase 1 |
Background: In vitro studies suggest that low levels of amplitude-modulated electromagnetic fields may modify cell growth. We have identified specific frequencies that may block cancer cell growth. We have developed a portable and programmable device delivering low levels of amplitude-modulated electromagnetic fields. The device is connected to a spoon-like coupler, which is placed in the patient's mouth during treatment.
Methods: We will conducted a feasibility study consisting of three daily treatments. All patients with advanced solid tumors and measurable disease will be eligible, irrespective of prior treatments. Patients will be assessed with laboratory exams (complete blood count, comprehensive profile, tumor markers), imaging studies every other month for the first six months, every third month thereafter.
Study Type : | Interventional (Clinical Trial) |
Enrollment : | 2 participants |
Allocation: | Non-Randomized |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Official Title: | Treatment of Advanced Cancer With Amplitude-modulated Electromagnetic Fields of Low Intensity by Means of an Intrabuccal Probe |
Study Start Date : | October 2004 |
Actual Primary Completion Date : | September 2006 |
Actual Study Completion Date : | December 2007 |
- Safety of daily administration of amplitude-modulated electromagnetic fields in patients with advanced cancer
- Complete blood count, comprehensive chemistry profile, tumor markers
- Tumor assessment as per RECIST criteria

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 95 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Advanced tumor that is either metastatic or inoperable
Exclusion Criteria:
- Pregnancy,
- Other simultaneous anticancer therapies,
- ECOG performance status less than 3

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00440570
Switzerland | |
Cabinet Médical Avenue de la gare 6 | |
Lausanne, Vaud, Switzerland, 1012 |
Principal Investigator: | Boris C Pasche, MD, PhD | Cabinet Médical Avenue de la gare 6 |
Responsible Party: | Boris Pasche |
ClinicalTrials.gov Identifier: | NCT00440570 |
Other Study ID Numbers: |
001 |
First Posted: | February 27, 2007 Key Record Dates |
Last Update Posted: | June 29, 2011 |
Last Verified: | June 2011 |
cancer electromagnetic fields treatment |
Brain Neoplasms Central Nervous System Neoplasms Nervous System Neoplasms Neoplasms by Site |
Neoplasms Brain Diseases Central Nervous System Diseases Nervous System Diseases |